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To the Editor
There is currently no standard of care for recurrent glio-
blastoma. Accordingly, there is an urgent medical need for
new therapeutic approaches in this setting. Novel treatment
approaches are often received with great hopes by patients
and relatives. Nevertheless, it is mandatory that all novel
treatment approaches, not only pharmacological treat-
ments, are subjected to standardized evaluations of safety
and efficacy.
In this regard, German neuro-oncologists have been
exposed to pressure from patients and relatives to introduce
the new therapy referred to as intratumoral thermotherapy,
developed by MagForce Nanotechnologies, for many
years. Finally and fortunately, data of a ‘‘phase II trial’’
were recently published in the Journal of Neuro-Oncology
[1]. In contrast to the title of this article, we would like to
point out that neither safety nor efficacy were
demonstrated:
(i) Safety was an issue. 15 patients experienced epileptic
seizures in the context of the treatment. Even the
authors raise the possibility that patients might benefit
from prophylactic anticonvulsants if they opt for this
treatment modality. From the quality of life perspec-
tive, it is important to note that all metallic materials
including dental fillings, crowns and implants within
40 cm of the treatment area had to be removed, for
safety reasons.
(ii) Efficacy could not be demonstrated simply as a
consequence of the study design. The experimental
treatment was combined with fractionated stereotac-
tic radiotherapy at 30 Gy in 2 Gy fractions. The
combination of an experimental treatment modality
with an established treatment modality like stereo-
tactic radiotherapy in an uncontrolled phase II trial is
inappropriate to demonstrate efficacy.
(iii) 24 of 59 patients had some treatment (resection 11,
radiotherapy 2, chemotherapy 17) for the same
recurrence subsequently treated with intratumoral
thermotherapy. No effort was made to dissect the
role of the various treatment measures administered
at recurrence.
(iv) The authors indicate that ‘‘data on any subsequent
treatments for tumor progression following the
thermo/radiotherapy were not systematically col-
lected’’. Accordingly, the impact of the experimental
treatment on the overall survival estimate is impos-
sible to evaluate. Progression-free survival was not
assessed and cannot easily be addressed since this
treatment precludes further MRI monitoring for life
because of artefact. Yet, overall survival at 2 years
from recurrence was the primary end point and
additional treatment measures at further recurrence
are likely to have influenced the treatment results.
(v) The authors state that analysis was by intention to
treat, but it remains unclear what happened to the
seven patients that were included, but did not fulfil
inclusion criteria. Curiously, analysis of efficacy is
based on 59 patients whereas analysis of safety is on
66 patients.
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Some minor comments need to be made, too:
(vi) The authors claim that randomization for recurrent
glioblastoma is ‘‘extremely difficult’’ and that a
randomized assessment of intratumoral thermother-
apy was not possible. This statement is proven wrong
by the series of randomized trials in that setting that
have been performed in the recent years, both using
local treatments such as immunotoxins or chemo-
therapy, e.g. for cilengitide [2], erlotinib [3], enzas-
taurin [4] or cediranib [5].
(vii) The authors cite Stummer et al. [6] as a reference for
the value of surgery for recurrent glioblastoma
which is not the content of this work.
(viii) The hypothesis that PET and SPECT are as good as
MRI to monitor disease progression has never been
addressed in a clinical study.
Altogether, this trial has a study design that a priori did
not allow to draw conclusions regarding efficacy. Yet,
substantial efforts are made in claiming efficacy in the
Discussion section, based on historical comparisons which
are inappropriate. This unjustified claim of efficacy is
worrisome because two of the authors are employees of
MagForce Nanotechnologies. This is mentioned as a dis-
closure, but the conflict of interest section says ‘‘none’’.
Michael Weller, Zurich, Switzerland
Wolfgang Wick, Heidelberg, Germany
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